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Abstract Pigmented villonodular synovitis (PVNS) is a
benign, translocation-derived neoplasm. Because of its
high local recurrence rate after surgery and occurrence of
osteochondral destruction, a novel therapeutic target is re-
quired. The present study aimed to evaluate the significance
of protein expression possibly associated with the pathogene-
sis during the clinical course of PVNS. In 40 cases of PVNS,
positivity of colony-stimulated factor 1 (CSF1), its receptor
(CSF1R), and receptor activator of nuclear factor kappa-B
ligand (RANKL) were immunohistochemically determined.
The relationship between the positivity and clinical outcomes
was investigated. High positivity of CSF1 staining intensity
was associated with an increased incidence of osteochondral
lesions (bone erosion and osteoarthritis) (p=0.009), but not
with the rate of local recurrence. Positivity of CSF1R and
RANKL staining was not associated with any clinical vari-
ables. The number of giant cells was not correlated with pos-
itivity of any of the three proteins, or with the clinical out-
come. Focusing on knee cases, CSF1 positivity was also as-
sociated with the incidence of osteochondal change (p=0.02).
CSF1R positivity was high in cases which had local recur-
rence, but not significantly so (p=0.129). Determination of
CSF1 and CSF1R expression may be useful as a prognostica-
tor of the clinical course and/or outcomes of PVNS.
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Introduction
Pigmented villonodular synovitis (PVNS), also known as
diffuse-type giant cell tumor, is a rare proliferative synovial
disease [1]. It usually occurs around the large joints such as the
knees and hips, and often results in hemarthrosis and/or
osteochondral destruction [2, 3]. Surgical resection is usually
performed, but the recurrence rate is high [4]. Histologically,
these tumors exhibit an infiltrative growth pattern and are
composed of various proportions of mononuclear cells, mul-
tinuclear osteoclast-like giant cells, foamy macrophages, and
siderophages [5]. The pathogenesis of PVNS, neoplastic or
reactive proliferation, has been discussed. Vogrinic et al. con-
cluded that giant cell tumor of tendon sheath is a non-neoplas-
tic, polyclonal proliferative lesion [6]. On the other hand, cy-
togenetic analyses have revealed structural aberration of 1p11-
13 in PVNS [7–9]. West et al. identified the translocation of
chromosome 1 that involves the CSF1 gene with COL6A3 on
chromosome 2. Additionally, FISH and immunohistochemi-
cal analyses indicated that a minority (2–16 %) of the cells
harbor the translocation and overexpress CSF1. Meanwhile,
overexpression of CSF1 receptor (CSF1R) positive cells has
been observed in tumorous tissues [10] and high expression
levels of CSF1 mRNA in PVNS [11]. These observations
suggest that translocation of CSF1 and COL6A3 induces high
expression of CSF1, which in turn attracts non-neoplastic cells
which express CSF1R.
The colony-stimulating factor 1 (CSF1) is known as a cy-
tokine that influences monocyte/macrophage differentiation
and the inflammatory process [12, 13]. Myeloid lineage cells
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comprising monocytes, macrophages, and osteoclasts have
the CSF1 receptor (CSF1R), and CSF1/CSF1R signaling
pathway is essential to the growth and differentiation of these
cells.
The multinucleated giant cells are variously expressed in
the PVNS tissue. Taylor et al. showed that multinucleated
giant cells have an osteoclast-like phenotype and are associat-
ed with bone resorption [14], which is one of the crucial
events in PVNS. The multinucleated giant cells are formed
by fusion of monocyte/macrophage precursors derived from
bone marrow. CSF1 plays an important role in osteoclast for-
mation with receptor activator of nuclear factor kappa-B li-
gand (RANKL) [15]. Because PVNS tissue expresses both
CSF1 and RANKL [5], higher expression of these factors
may result in the overexpression of osteoclast-like multinucle-
ated cells and induce bone resorption and joint destruction in
some cases. However, no studies have ever investigated the
correlation of CSF1, CSF1R, and RANKL expression with
the clinical features and course of PVNS.
In this study, we aimed to determine the expression of
CSF1, CSF1R, and RANKL in PVNS tissues by immu-
nohistochemistry and reveal the relationship between stain-
ing positivity and clinical features including occurrence of
osteochondral lesions (bone erosion and/or osteoarthritis)
and local recurrence after surgery. Additionally, we evaluated
the number of giant cells and tumor volume and analyzed the
association with various clinical variables.
Materials and methods
Clinical data
We collected clinical information from the patient database of
78 PVNS cases referred to our institutions between 1987 and
2014. Excluding cases with insufficient medical records, or
not treated surgically, 40 cases, which were histologically
diagnosed as PVNS by an experienced pathologist in our
institution (YS) and had a specimen available for immu-
nohistochemical analysis, were enrolled in this study.
Information regarding age, sex, involved joints, occurrence
of osteochondral lesions (bone erosion and osteoarthritis),
and local recurrence were retrieved from the medical records.
Institutional review board in our institution approved this
study (approved number: 1332).
Surgical treatment
Diffuse PVNS was treated as a rule with open tumor excision.
Diffuse knee lesions were treated with open anterior and/or
posterior total tumor excision until 2008. Subsequently, dif-
fuse knee lesions were treated with arthroscopic anterior
synovectomy and open excision of posterior lesions. In the
localized type of PVNS, the tumor was simply resected en
bloc. Patients received neither radiotherapy nor chemotherapy
for PVNS.
Immunohistochemistry
PVNS tissues were obtained at the time of surgery for
immunohistological analysis. Tissues were fixed in 10 %
formalin and embedded in paraffin. Immunohistochemical
studies were conventionally performed using a streptavidin-
biotin complex technique using formalin-fixed, paraffin-
embedded sections. Paraffin specimens were cut at a thickness
of 4 μm. The deparaffinized and rehydrated sections were
treated with 0.3 % hydrogen peroxide in methanol for
15 min at room temperature to block the internal peroxidase
activity followed by soaking in 10 % normal goat serum as a
blocking agent for 10 min. The slides were incubated at 4 °C
for 12 h with primary rabbit polyclonal antibodies, which have
been confirmed to react with human target proteins. Primary
antibodies were as follows: anti-CSF1 (ab9693; Abcam,
Cambridge, UK; 1:100 dilution), anti-CSF1R (ab61137;
Abcam, 1:100 dilution), and anti-RANKL (bs-0747R; Bioss
MA, USA, 1:250 dilution). After rinsing with PBS, the sec-
tions were incubated with biotinylated anti-rabbit IgG conju-
gated with peroxidase as a second antibody, and the reaction
products were observed using 3,3′-diaminobenzidine tetrahy-
drochloride. In cases in which a high deposition of hemosid-
erin was observed, Berlin blue staining was additionally per-
formed. Slides were counterstained with hematoxylin,
dehydrated, and mounted. Nonimmune goat serum was
substituted for the primary antibody to serve as a negative
control. Two orthopedic surgeons (TO, SH) and an experi-
enced pathologist (YS) without knowledge of the clinicopath-
ologic information evaluated the results of the immunohisto-
chemical staining. Positive cells were counted individually in
three different areas under a light microscope at ×400 magni-
fication. Mean numbers of positively stained cells and total
cells were calculated. The positive cell ratio (positive cell
number/total cell number in the field) was determined.
Positivity of the staining was divided into two groups: high
and low according to the calculated mean value of the positive
ratio.
Evaluation of multinucleated giant cells
Since it is presumed that multinucleated giant cells have
significant pathogenetic roles in not only the develop-
ment of tumors but also of ostechondral lesions, their
number was determined in 10 randomly selected fields
in the specimen under a light microscope at ×100 mag-
nification. We classified the results of the cell count as low
(=<50 cells/field) or high (>50).
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Assessment of tumor volume
We determined the tumor volume using magnetic resonance
(MR) or computed tomography (CT) images in 29 measurable
cases. Eleven cases were excluded, because of difficulty with
the tumor volume measurement (not massive form) or a lack of
imaging data. The maximum cross-sectional diameter (axial;
R1, sagittal; R2, coronal; R3) was measured. We assumed the
tumor to be oval-shaped and calculated the volumewith a math-
ematical formula (4/3π×R1×R2×R3). In cases with multiple
lesions, we added them up. The tumor volume was classified
into two groups: small (=<50 cm3) or large tumor (>50 cm3).
Statistical analysis
Statistical analysis was performed using SPSS™ software,
version 22.0. Fisher’s exact test and Pearson’s chi square test
were applied to determine correlations between each of the
variables (CSF1 expression, CSF1R expression, RANKL ex-
pression, the number of multinucleated giant cells, and tumor
volume) and clinical features (gender, age, tumor localization,
occurrence of osteochondral lesions, and recurrence of tumor).
P values <0.05 were considered significant.
Results
Themean age of patients was 35 years, ranging from 8 to 63 at
the time of operation. Twenty-six patients were female and 14
were male. Knee joints were affected in 25 cases, hip in 6, foot
and ankle in 4, elbow in 2, and shoulder, thigh, and sternocos-
tal joints in one each (Table 1). Skeletal alterations (bone
erosion and/or osteoarthritic change) were observed in 13
cases at the time of presentation or during the clinical course
(6 cases: knee joints, 5; hip, 2; ankle 1). Three (2 hip joints, 1
knee joint) of 13 cases underwent total joint replacement sur-
gery. Ten cases developed local recurrence (8 cases of knee
joints, 2 of ankle joint).
Immunohistochemical staining for CSF1, CSF1R,
and RANKL
CSF1 expression
CSF1 was positive in all cases (Fig. 1). Positive staining was
observed mainly in mononuclear cells and some multinuclear
giant cells. Mean positive rate was 7 % (range 3–15 %).
Positivity of CSF1 staining was classified as high or low ac-
cording to the cutoff value of 7 %. The cutoff value deter-
mined by receiver operatorating characteristic value analysis
was also 7 %, suggesting that this value was adequate. In the
13 cases with osteochondral lesions, high positivity of CSF1
staining was observed in 11 cases (85 %). High positivity of
CSF1 was significantly correlated with osteochondral lesions
(p=0.009) (Table 2), but not with local recurrence (p=1)
(Table 3). CSF1 immunostaining positivity was not statistical-
ly correlated with the number of giant cells, tumor volume,
gender, age, or tumor localization.
CSF1R expression
CSF1R was positive in all cases (Fig. 1). CSF1R stainability
varied widely among cases and areas. Positive staining was
observed in mononuclear and multinuclear giant cells (Fig. 1).
The mean positive CSF1R staining rate was 10 % (range 6–
22%). Positivity was divided into high and low groups accord-
ing to the mean positive value (10 %). None of the clinical
variables analyzed were significantly correlated with CSF1R
positivity including osteochondral lesions (p=1) (Table 2).
CSF1R staining intensity was observed in 9 (90 %) of the 10
cases with local recurrence; however, it did not reach statistical
significance (p=0.124) (Table 3). Positivity of CSF1R immu-
nostaining was not statistically correlated with the number of
giant cells, tumor volume, gender, age, or tumor localization.
RANKL expression
Positivity for RANKLwas observed in all cases. Somemono-
nuclear cells and multinuclear giant cells were stained (Fig. 1).
Table 1 Demographic
data of 40 cases
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The mean value of the positivity was 9 % (range 4–15 %).
Interestingly, RANKL positivity was not statistically correlat-
ed with the occurrence of osteochondral change including
bone erosion (Table 2), recurrence of tumors (Table 3), the
number of giant cells, tumor volume, gender, age, or tumor
localization.
Multinucleated giant cells
The number of multinucleated giant cells varied widely
among cases. The mean number of multinucleated giant
cells was 67/field ranging from 0 to 243 (Fig. 2). The
number of multinucleated giant cells was divided into high
and low groups according to the mean numbers. There
was no significant difference in the number of giant cells
between the presence and absence of osteochondral change
(Table 2), recurrence of tumors (Table 3), gender, age, or
tumor localization.
Tumor volume
In 29 cases with measurable tumor volume, the median
tumor volume was 48 cm3 ranging from 2 to 330 cm3.
The tumor volume was divided into small and large
groups according to the mean volume. Statistical analyses
revealed that tumor volume was not associated with
osteochondral change (Table 2), local recurrence (Table 3),
gender, age, or tumor localization.
Table 2 Factors correlated with the occurrence of osteochondral
lesions

















a Fisher’s exact test and Pearson chi square test were used to examine
correlation with each variables
Table 3 Factors correlated with the recurrence of tumors

















a Fisher’s exact test and Pearson chi square test were used to examine
correlation with each variable
Fig. 1 Immunohistochemical staining of PVNS. Photomicrographs
show immunostaining of CSF1 (a, b), CSF1R (c, d), RANKL (e, f) in
PVNS tissues. Low (a, c, e) and high (b, d, f) positivity of expression
(counterstain with hematoxylin; original magnification, ×400)
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Subgroup analysis
We focused on cases with knee joint involvement, because the
highest rates of incidence and recurrence were observed in this
joint in the present study. All of the six cases developing
osteochondral lesions showed high positivity for CSF1 stain-
ing (p=0.02) (Table 4). All of the eight cases with local recur-
rence showed high positivity for CSF1R staining, but without
reaching statistical significance (p=0.129) (Table 5). RANKL
staining intensity was associated with neither increased occur-
rence of osteochondral lesions (p=1) nor local recurrence
(p=0.667). The number of giant cells and tumor volume were
not associated with osteochondral lesions or tumor recurrence.
Discussion
Problems developing in the clinical course of PVNS include
ostechondral destruction [3] and high recurrence rate [16, 17].
Previous studies reported some risk factors possibly implicat-
ed in the aggressive behavior of PVNS (osteochondral de-
struction and high recurrence rate) including expression of
matrix metalloproteinases (MMPs) [18, 19] and osteoclast-
like cells induced by CSF1 and RANKL [14]. However, no
previous studies have analyzed the relationship between the
aggressive behavior of PVNS and expression patterns of cell
types positive for CSF1, CSF1R, and RANKL, which might
be pathogenetic determinants of PVNS [10, 12, 14]. We spec-
ulated that these molecules might be possible prognosticators
of the aggressiveness of PVNS. The present study analyzed
for the first time the possible correlation between the expres-
sion levels of CSF1, CSF1R, and RANKL with the clinical
course of PVNS and demonstrated that high expression of
CSF1 was significantly correlated with a high incidence of
osteochondral change, while cases with high expression levels
of CSF1R tended to have a high rate of local recurrence of
knee PVNSs. Although other factors may be involved in the
Table 4 Factors correlated with the occurrence of osteochondral
lesions in knee cases

















a Fisher’s exact test and Pearson chi square test were used to examine
correlation with each variables
Table 5 Factors correlated with the local recurrence of tumors in knee
cases

















a Fisher’s exact test and Pearson chi square test were used to examine
correlation with each variable
Fig. 2 Multinucleated giant cells in PVNS. Photomicrographs show
representative samples to count the number of giant cells. No
multinucleated giant cells are observed, even at high magnification (a, c).
A large number of multinucleated giant cells are seen, even at low
magnification (b, d) (original magnification, ×100 (a, b), ×200 (c, d))
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development of osteochondral destruction [3, 14, 18, 20], the
findings of the present study may provide novel insights into
the roles of CSF1 and CSF1R regarding not only the biolog-
ical profiles of PVNS but also underlying data for assessing
the efficacy of future biological agents for PVNS such as anti-
CSF1R antibody.
The PVNS synovial tissue contains diverse cell types, com-
posed of mononuclear cells and multinucleated giant cells.
Several previous studies analyzed the cell characterization
and cytokine expression in PVNS. Yoshida et al. investigated
characteristics of cells constituting PVNS [5]. In their results,
CSF1 and RANKL were expressed in both mononuclear and
multinuclear giant cells, which were positive for CD68, a
macrophage/histiocyte marker. Multinucleated giant cells
expressed osteoclastic markers including TRAP, suggesting
that mononuclear cells mediate the differentiation of osteo-
clasts from mononuclear cells via expression of CSF1 and
RANKL. Several other studies also determined the character-
istics of macrophage marker CD14 positive and negative
mononuclear cells and multinucleated giant cells in PVNS
[14, 21]. Taylor et al. showed that multinucleated giant cells
are formed fromCD14 positive cells and express an osteoclast
phenotype. CD14 negative mononuclear cells that express
RANKL and CSF1 support osteoclast formation [14]. The
results of their study also indicated that osteoclast formation
occurred even in the absence of exogenous CSF1, suggesting
that overexpression of CSF1 in component cells might
have a pathogenic role in PVNS. These findings are in
part consistent with those of the present study in which
osteochondral destruction occurred more often in cases
with higher expression of CSF1.
In the experience of many physicians, osteochondral
destruction does not develop in so many PVNS cases,
while the frequency of osteochondral change is highly
correlated with the site of PVNS involvement. A previous
study identified a factor influencing osteochondral destruc-
tion in PVNS patients, namely, a limited joint space such
as that present in the hips, feet, and ankles, which is
significantly correlated with the occurrence of osteochondral
destruction [3]. In the current study, most of the cases with hip
joint involvement developed bone destruction and/or osteoar-
thritic change. We considered that a subgroup analysis should
be performed focusing on cases with knee joint involvement,
where the factor of joint volume might not affect the oc-
currence of osteochondral destruction. CSF1 was still sig-
nificantly associated with the occurrence of osteochondral
destruction in knee cases and was considered to be a risk
factor. Interestingly, tumor volume was not associated with
the occurrence of osteochondral events in knee joint, which
has a large joint capacity (Table 2).
PVNS has a high local recurrence rate despite being a be-
nign neoplasm [16, 22]. However, no investigations have yet
analyzed the relationship between the molecular pathogenetic
background, such as a CSF1/CSF1R signaling pathway, and
the local recurrence rate of PVNS. Translocation of CSF1 in
PVNS and subsequent CSF1 overexpression have been impli-
cated in the pathogenesis of PVNS [9, 12]. West et al. de-
scribed that CSF1-overexpressed tumor cells recruit CSF1R
positive stromal cells through autocrine and paracrine path-
ways, leading to tumor formation, known as a Blandscape
effect^ [10]. Large numbers of CSF1R positive cells in
PVNS may reflect the higher recruitment activity of tumors.
The results of the present study focusing on knee cases, where
a higher relapse rate was observed, revealed that CSF1R ex-
pression was high in all relapsed knee cases, but not signifi-
cantly so (p=0. 129) probably due to the small numbers of
cases. Further study is needed to obtain the definitive correla-
tion between CSF1R expression and local recurrence.
Recently, several studies have investigated CSF1R as a pos-
sible therapeutic target in PVNS [23–27]. Blay et al. reported
that treatment with imatinib mesylate achieved a complete re-
sponse in cases of recurrent PVNS [26]. Cassier et al. reported
the efficiency of imatinib mesylate in the treatment of locally
advanced PVNS [27]. However, these recent studies did not
investigate the predictive value of the expression level of CSF1
or CSF1R regarding the efficacy of the agent, while the present
study provides novel information on the predictive value of
pathogenetic molecules in the clinical course of PVNS.
The present study has several limitations. Due to the rarity
of this disease, the study population was composed of only a
small number of cases and a retrospective cohort. Larger num-
ber of cases is required to draw a definitive conclusion by
multi-institutional study. There were several cases of diffuse
type PVNS, which were excluded from the measurements of
tumor volume because of the difficulty in evaluating this type.
The results of the immunohistochemical analysis may have
been influenced by the heterogeneity of the obtained samples,
sensitivity of the antibody, and staining protocol. However,
the immunohistochemistry results would be more consistent
if performed with the same antibody, protocol, and skilled
technique.
In conclusion, the present study, for the first time, investi-
gated the possible correlation between the clinical course of
PVNS and expression of pathogenetic molecules including
CSF1 and CSF1R. The results suggested that a high positivity
of CSF1 staining may predict the occurrence of osteochondral
destruction in PVNS. Further investigation may help to clarify
not only the possible correlation of CSF1 and CSF1R expres-
sion and clinical course of PVNS, but also the predictive value
of the expression, thereby facilitating the development of op-
timal molecular target therapies.
Acknowledgments We thank Miss Eri Ishihara for secretarial assis-
tance regarding this study. This work was supported by the Grant-in-
Aid for Ministry of Education, Culture, Sports, Science and Technology
of Japan [Grant-in-Aid 26293334 for Scientific Research (B)].
5366 Tumor Biol. (2015) 36:5361–5367
Conflicts of interest None
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. Jaffe H, Lichtenstein L, Sutro C. Pigmented villonodular synovitis,
bursitis and tenosynovitis. Arch Pathol. 1941;31:731–65.
2. Geldyyev A, Koleganova N, Piecha G, Sueltmann H, Finis K,
Ruschaupt M, et al. High expression level of bone degrading proteins
as a possible inducer of osteolytic features in pigmented villonodular
synovitis. Cancer Lett. 2007;255:275–83.
3. Nishida Y, Tsukushi S, Nakashima H, Sugiura H, Yamada Y,
Urakawa H, et al. Osteochondral destruction in pigmented
villonodular synovitis during the clinical course. J Rheumatol.
2012;39:345–51.
4. Ravi V, Wang W-L, Lewis VO. Treatment of tenosynovial giant cell
tumor and pigmented villonodular synovitis. Curr Opin Oncol.
2011;23:361–6.
5. Yoshida W, Uzuki M, Kurose A, Yoshida M, Nishida J,
Shimamura T, et al. Cell characterization of mononuclear and
giant cells constituting pigmented villonodular synovitis. Hum
Pathol. 2003;34:65–73.
6. Vogrincic GS, O’Connell JX, Gilks CB. Giant cell tumor of tendon
sheath is a polyclonal cellular proliferation. Hum Pathol. 1997;28:
815–9.
7. Sciot R, Rosai J, Dal Cin P, de Wever I, Fletcher CD, Mandahl N,
et al. Analysis of 35 cases of localized and diffuse tenosynovial giant
cell tumor: a report from the Chromosomes and Morphology
(CHAMP) study group. Mod Pathol. 1999;12:576–9.
8. Nilsson M, Höglund M, Panagopoulos I, Sciot R, Dal Cin P, Debiec-
Rychter M, et al. Molecular cytogenetic mapping of recurrent chro-
mosomal breakpoints in tenosynovial giant cell tumors. Virchows
Arch. 2002;441:475–80.
9. Möller E, Mandahl N, Mertens F, Panagopoulos I. Molecular identi-
fication of COL6A3-CSF1 fusion transcripts in tenosynovial giant
cell tumors. Gene Chrom Cancer. 2008;47:21–5.
10. West RB, Rubin BP, Miller MA, Subramanian S, Kaygusuz G,
Montgomery K, et al. A landscape effect in tenosynovial giant-cell
tumor from activation of CSF1 expression by a translocation in a
minority of tumor cells. Proc Natl Acad Sci U S A. 2006;103:690–5.
11. Molena B, Sfriso P, Oliviero F, Pagnin E, Teramo A, Lunardi F, et al.
Synovial colony-stimulating factor-1 mRNA expression in diffuse
pigmented villonodular synovitis. Clin Exp Rheumatol. 2011;29:
547–50.
12. Cupp JS, Miller MA, Montgomery KD, Nielsen TO, O’Connell JX,
Huntsman D, et al. Translocation and expression of CSF1 in
pigmented villonodular synovitis, tenosynovial giant cell tumor,
rheumatoid arthritis and other reactive synovitides. Am J Surg
Pathol. 2007;31:970–6.
13. Nakano K, Okada Y, Saito K, Tanikawa R, Sawamukai N, Sasaguri
Y, et al. Rheumatoid synovial endothelial cells produce macrophage
colony-stimulating factor leading to osteoclastogenesis in rheumatoid
arthritis. Rheumatology (Oxford). 2007;46:597–603.
14. Taylor R, Kashima TG, Knowles H, Gibbons CLMH, Whitwell D,
Athanasou NA. Osteoclast formation and function in pigmented
villonodular synovitis. J Pathol. 2011;225:151–6.
15. Sarma U, Flanagan AM. Macrophage colony-stimulating factor in-
duces substantial osteoclast generation and bone resorption in human
bone marrow cultures. Blood. 1996;88:2531–40.
16. Ma X, Shi G, Xia C, Liu H, He J, Jin W. Pigmented villonodular
synovitis: a retrospective study of seventy five cases (eighty one
joints). Int Orthop. 2013;37:1165–70.
17. Aurégan J-C, Klouche S, Bohu Y, Lefèvre N, Herman S, Hardy P.
Treatment of pigmented villonodular synovitis of the knee.
Arthroscopy. 2014;30(10):1327–41.
18. Uchibori M, Nishida Y, Tabata I, Sugiura H, Nakashima H, Yamada
Y, et al. Expression of matrix metalloproteinases and tissue inhibitors
of metalloproteinases in pigmented villonodular synovitis suggests
their potential role for joint destruction. J Rheumatol. 2004;31:110–9.
19. O’Keefe RJ, Rosier RN, Teot LA, Stewart JM, Hicks DG. Cytokine
and matrix metalloproteinase expression in pigmented villonodular
synovitis may mediate bone and cartilage destruction. Iowa Orthop J.
1998;18:26–34.
20. Weckauf H, Helmchen B, Hinz U, Meyer-Scholten C, Aulmann S,
Otto HF, et al. Expression of cell cycle-related gene products in dif-
ferent forms of primary versus recurrent PVNS. Cancer Lett.
2004;210:111–8.
21. Avnet S, Salerno M, Zini N, Alberghini M, Gibellini D, Baldini N.
Sustained autocrine induction and impaired negative feedback of
osteoclastogenesis in CD14(+) cells of giant cell tumor of bone.
Am J Pathol. 2013;182:1357–66.
22. Chin KR, Barr SJ, Winalski C, Zurakowski D, Brick GW. Treatment
of advanced primary and recurrent diffuse pigmented villonodular
synovitis of the knee. J Bone Joint Surg Am. 2002;84-A:2192–202.
23. Cheng H, Clarkson PW, Gao D, Pacheco M, Wang Y, Nielsen TO.
Therapeutic antibodies targeting CSF1 impede macrophage recruit-
ment in a xenograft model of tenosynovial giant cell tumor. Sarcoma.
2010;2010:174528.
24. Stacchiotti S, Crippa F, Messina A, Pilotti S, Gronchi A, Blay JY,
et al. Response to imatinib in villonodular pigmented synovitis
(PVNS) resistant to nilotinib. Clin Sarcoma Res. 2013;3:8.
25. Dewar AL, Cambareri AC, Zannettino ACW, Miller BL, Doherty
KV, Hughes TP, et al. Macrophage colony-stimulating factor receptor
c-fms is a novel target of imatinib. Blood. 2005;105:3127–32.
26. Blay J-Y, El Sayadi H, Thiesse P, Garret J, Ray-Coquard I. Complete
response to imatinib in relapsing pigmented villonodular synovitis/
tenosynovial giant cell tumor (PVNS/TGCT). Ann Oncol. 2008;19:
821–2.
27. Cassier PA, Gelderblom H, Stacchiotti S, Thomas D, Maki
RG, Kroep JR, et al. Efficacy of imatinib mesylate for the
treatment of locally advanced and/or metastatic tenosynovial
giant cell tumor/pigmented villonodular synovitis. Cancer.
2012;118:1649–55.
Tumor Biol. (2015) 36:5361–5367 5367
